Pacific Biosciences of California promotes high accuracy HiFi sequencing to power AI driven drug discovery

Pacific Biosciences of California promotes high accuracy HiFi sequencing to power AI driven drug discovery
HiFi sequencing drives AI drug discovery

Pacific Biosciences of California is advancing the integration of artificial intelligence in drug discovery by emphasizing the need for robust, high quality data.

The company advocates that its HiFi sequencing technology delivers a rich multiomic dataset, providing the depth and accuracy that AI models require to enable breakthroughs in the biopharma sector. Pacific Biosciences of California asserts that without foundational data integrity, even the most sophisticated AI models will fall short in transforming drug development. According to the company, enhanced sequencing methods could become central to biopharma innovation as machine learning matures within the industry.

Pacific Biosciences of California recently analyzed differences in benchmarking, variant calling, and phasing between Illumina TruPath and PacBio HiFi WGS using the HG002 standard, according to a company comparison. The firm was also featured in a Cell special issue highlighting 13 new complete genome assemblies achieved with its technology, as detailed in a previous report. These developments reflect ongoing activity surrounding PacBio’s sequencing platforms in research and biopharma collaborations.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.